The global Hematopoietic Stem Cell Transplantation Market is worth US$ 7 Billion as of now and is expected to reach US$ 15 Billion by the year 2033 at a CAGR of 8% between 2023 and 2033.
With the rise in the geriatric population, the probability of contracting hematopoietic stem cells abounds. This factor is expected to keep the cash registers ringing for the hematopoietic stem cell transplantation market in the forecast period. Plus, there is an exorbitant increase in healthcare expenditure all across. There is also provision for patient analysis, cures, and prognosis.
At the same time, the fact that initial costs involved in stem cell transplantation are high can’t be ignored. This factor is expected to restrain the hematopoietic stem cell market in the forecast period.
Click here to claim your report with captivating visuals. @
https://www.futuremarketinsights.com/reports/sample/rep-gb-16462
Future Market Insights has etched these facets with future prospects in its latest market study entitled ‘Hematopoietic stem cell transplantation market’. It has a team of analysts and consultants to deploy a 360-degree approach across macros and micros.
“With incidences of lymphoma and leukemia in an aplomb, the global hematopoietic stem cell transplantation market is expected to grow on an unstoppable note in the forecast period”, says an analyst from Future Market Insights.
Key Takeaways from Hematopoietic Stem Cell Transplantation Market
- North America holds the largest market share due to growing incidences of myeloma, lymphoma, or leukemia all over the US. This is evident from the fact that as per the ‘Leukemia and Lymphoma Society’, over 172,910 people all across the US are suffering from myeloma, lymphoma, or leukemia.
- The Asia-Pacific is expected to grow in the hematopoietic stem cell transplantation market on the back of Japan. This is shown by the fact that the Japanese Data Center for Hematopoietic Cell Transplantation has mentioned that Japan witnessed the maximum number of transplants in the Asia-Pacific.
Competitive Transplantation:
- Ankyra is in the development of Anchored Immunotherapy (a cytokine suppression-based immunotherapy). It claims to boost cytokine immunotherapy’s effectiveness.
- OXvax is developing a DC (dendritic cell) immune-oncology vaccination platform. It does generate huge quantities of CD141+XCR1 DC subset from the induced pluripotent stem cells using an exclusive methodology (iPSC).
- Catamaran Bio makes provisions for TAILWIND, which comes across as a patented technology package for manufacturing and engineering NK cells. NK cells are programmed using synthetic biotechnology-enabled tumor microenvironment (TME) switches with the TcBuster transposon system.
- Taiga Biotechnologies, in November 2021, did announce that the very first site based out of Croatia finished with a site initiation session for the TBX-2400-01 clinical trial, a Phase ½ study for evaluating early efficacy and safety of TBX-2400 in AML (acute myeloid leukemia) and myelofibrosis patients who are going through HSCT (hematopoietic stem cell transplant).
- Lonza, in November 2022, came up with a capsule solution for administering an enteric drug called ‘The Capsugel EnprotectTM’. The interesting part herein is that it is insoluble in water and does release contents solely in the intestine. Capsugel EnprotectTM capsules thus do away with the requirement for additional capsule sealing or coating, thereby simplifying the process of medicinal product production.
- Regen BioPharma, in October 2022, did announce the filing of a provisional patent application with the USPTO entitled ‘Enhancement of T Cell Homing to Tumors’ through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion’ with the ‘US Patent and Trademark Office’.
- Takeda’s Phase 3 AURORA study, as of December 2022, does show that maribavir does have a clinically long-lasting effect on CMV (Cytomegalovirus) infection in those going through hematopoietic stem cell transplant.
- Priothera, in May 2022, did receive clearance from the US FDA regarding investigational new drug (IND) for starting with Phase 2b/3 study with mocravimod in AML (Acute Myeloid Leukemia) patients going through Allogeneic HSCT (Hematopoietic Stem Cell Transplant).
- The US FDA, in December 2021, did approve treatment regarding the prevention of acute graft-versus-host disease (GVHD) in patients aged 2 and above who are undergoing hematopoietic stem cell transplant from single or matched HLA-mismatched unrelated donors.
Enrich your thinking with our comprehensive methodology now. @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16462
What does the Report stem from?
- The research study is based on transplant type (autologous and allogeneic), by indication (acute myeloid leukemia, acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and other non-malignant disorders), and by application (bone marrow transplant, peripheral blood stem cells transplant, and cord blood transplant).
- With growing awareness about the importance of hematopoietic stem cell transplants, the global hematopoietic stem cell transplantation market is bound to grow on a sturdy note in the forecast period.
Key Companies Profiled:
- Pluristem Therapeutics Inc.
- CellGenix GmbH
- Regen Biopharma Inc.
- Lonza Group
- Sanofi
- Taiga Biotechnologies, Inc.
- Takeda Pharmaceutical Company Limited
- Escape Therapeutics, Inc.
- Bluebird Bio
- Talaris Therapeutics
Key Segments Profiled in the Hematopoietic Stem Cell Transplantation Market Industry Survey
By Transplant Type:
- Allogeneic
- Autologous
By Indication:
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Other Non-Malignant Disorders
By Application:
- Bone Marrow Transplant
- Peripheral Blood Stem Cells Transplant
- Cord Blood Transplant
Hematopoietic Stem Cell Transplantation Market by Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa (MEA)
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
